Technical Analysis for GLYC - GlycoMimetics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Stochastic Buy Signal | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | 9.38% | |
Oversold Stochastic | Weakness | 9.38% | |
Lower Bollinger Band Walk | Weakness | 7.28% | |
Inside Day | Range Contraction | 7.28% | |
Oversold Stochastic | Weakness | 7.28% |
Alert | Time |
---|---|
Possible Pocket Pivot | about 17 hours ago |
20 DMA Resistance | about 18 hours ago |
Rose Above 20 DMA | about 18 hours ago |
Up 10% | about 19 hours ago |
Up 1 ATR | about 19 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/27/2024
GlycoMimetics, Inc. Description
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Drug Discovery Acute Myeloid Leukemia Chemotherapy Clinical Trial Product Testing Pseudomonas Sickle Cell Disease Hematologic Cancers Nursing Research
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.5299 |
52 Week Low | 1.11 |
Average Volume | 328,846 |
200-Day Moving Average | 1.97 |
50-Day Moving Average | 3.00 |
20-Day Moving Average | 2.85 |
10-Day Moving Average | 2.70 |
Average True Range | 0.23 |
RSI (14) | 48.45 |
ADX | 20.62 |
+DI | 14.65 |
-DI | 17.75 |
Chandelier Exit (Long, 3 ATRs) | 2.67 |
Chandelier Exit (Short, 3 ATRs) | 3.19 |
Upper Bollinger Bands | 3.25 |
Lower Bollinger Band | 2.46 |
Percent B (%b) | 0.43 |
BandWidth | 27.83 |
MACD Line | -0.10 |
MACD Signal Line | -0.07 |
MACD Histogram | -0.0263 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.23 | ||||
Resistance 3 (R3) | 3.21 | 3.04 | 3.16 | ||
Resistance 2 (R2) | 3.04 | 2.93 | 3.05 | 3.14 | |
Resistance 1 (R1) | 2.92 | 2.86 | 2.98 | 2.94 | 3.11 |
Pivot Point | 2.75 | 2.75 | 2.78 | 2.76 | 2.75 |
Support 1 (S1) | 2.63 | 2.64 | 2.69 | 2.66 | 2.49 |
Support 2 (S2) | 2.46 | 2.57 | 2.47 | 2.46 | |
Support 3 (S3) | 2.34 | 2.46 | 2.44 | ||
Support 4 (S4) | 2.37 |